分析新药研发中的合作动态:对两种降脂药物的案例研究
Nan Zhang1, Huaqing Guo2, Mengchao Zhang1
1Department of Health Administration, School of Management, Shanxi Medical University, Taiyuan, China.
Frontiers in pharmacology
|June 16, 2025
概括
生物技术推动了药物开发合作,学术界和工业界的合作伙伴关系越来越多. 网络分析显示,临床研究合作的引用率较高,但在早期发展过渡阶段存在差距.
科学领域:
- 生物技术和制药科学 生物技术和制药科学
- 药物发现和开发 药物发现和开发
- 科学研究中的网络分析.
背景情况:
- 生物技术的进步正在推动学术,制药,医院和基金会部门的合作,以加速药物创新.
- 尽管越来越多的跨学科努力,科学和技术进步对这些研究合作的具体影响仍然不太清楚.
- 了解不断变化的协作动态对于优化药物开发管道至关重要.
研究的目的:
- 通过网络分析,分析药物开发中的研究合作的进化趋势.
- 调查合作对引用次数的影响,并确定不同研究阶段的模式.
- 检查包括大学,企业和医院在内的各种实体在生物制剂研发 (R&D) 中的作用.
主要方法:
- 案例研究重点是开发两种类型的降脂药物.
- 在作者,机构和国家层面进行网络分析,以绘制协作模式.
- 研究协作动态中的进化趋势的量化.
主要成果:
- 在学术链的临床部分的合作研究显示了更高的引用率.
- 在基础研究和后来的发展阶段之间观察到的合作联系较少.
- 大学-企业和大学-医院在生物制品研发方面的合作越来越普遍,受到相似性和接近性的影响.
- 发展中国家越来越多地参与国家和区域生物药物研发.
结论:
- 药物研发合作模式随着生产率的提高而动态发展.
- 加强制药公司参与早期研究至关重要.
- 加强学术链内的跨部门关系,提高研发到应用效率是未来药物创新的必要条件.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
890
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
890
Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Drug Discovery: Overview
8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Atherosclerosis III: Management
42
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
42
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Drug Biotransformation: Overview
3.0K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.0K


